Proficio Capital Partners LLC Has $6.13 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4,418.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 147,360 shares of the company's stock after purchasing an additional 144,099 shares during the quarter. Proficio Capital Partners LLC's holdings in Moderna were worth $6,127,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNA. Knuff & Co LLC increased its position in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company's stock worth $316,000 after purchasing an additional 244 shares in the last quarter. Stephens Inc. AR raised its stake in Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company's stock valued at $223,000 after purchasing an additional 245 shares during the last quarter. Allworth Financial LP lifted its position in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after buying an additional 281 shares during the period. Howard Capital Management Inc. grew its holdings in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after purchasing an additional 297 shares during the period. Finally, Larson Financial Group LLC increased its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock worth $61,000 after purchasing an additional 317 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 9.2 %

MRNA stock traded up $2.79 during midday trading on Wednesday, hitting $33.16. The stock had a trading volume of 14,761,242 shares, compared to its average volume of 12,435,021. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The stock has a 50-day simple moving average of $36.92 and a 200 day simple moving average of $49.88. The firm has a market capitalization of $12.79 billion, a price-to-earnings ratio of -3.58 and a beta of 1.86.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MRNA shares. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Friday, November 8th. HSBC raised Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Piper Sandler reiterated an "overweight" rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and decreased their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.